envafolimab

Drug Overview

Envafolimab is a modern Immunotherapy and a “Smart Drug” designed to help the body’s own immune system find and destroy cancer cells. It belongs to a specialized group of medicines called “checkpoint inhibitors.” A unique feature of this drug is its structure; it is a “nanobody,” which is much smaller than traditional antibodies, allowing it to be given as a simple injection under the skin rather than a long hospital drip.

• Generic Name: Envafolimab (also known as KN035)
• US Brand Names: None (Currently an Investigational Drug in the US; approved in other international markets as Enweida®)
• Drug Class: Programmed Death-Ligand 1 (PD-L1) blocking antibody; Nanobody
• Route of Administration: Subcutaneous (SC) Injection
• FDA Approval Status: Investigational. It has received “Orphan Drug” designation for specific cancers, but as of 2026, it is primarily available through clinical trials in the US and Europe.

What Is It and How Does It Work? (Mechanism of Action)

Envafolimab is a Targeted Therapy that works by uncovering “hidden” cancer cells. To understand how it works, imagine your immune system’s T-cells as soldiers guarding your body. Cancer cells are clever—they often produce a protein called PD-L1. This protein acts like a “secret handshake” or a shield that tells the T-cell soldiers, “I am a friend, do not attack me.”

At the molecular level, envafolimab follows this process:

1. Binding: The drug is engineered to specifically find and lock onto the PD-L1 receptors on the surface of the tumor cells.
2. Removing the Brakes: By covering these receptors, envafolimab blocks the cancer from connecting with the PD-1 receptor on the T-cells.
3. Immune Reactivation: Once this connection is blocked, the “brakes” are taken off the immune system. The T-cells realize the cancer is an intruder and begin to multiply and attack the tumor.
4. Nanobody Advantage: Because envafolimab is a “single-domain” antibody (nanobody), it is much smaller than standard drugs in this class. This allows for Subcutaneous Administration, meaning it can be injected quickly into the fatty tissue under the skin, usually in the thigh or abdomen, rather than requiring an hour-long intravenous (IV) session.

FDA-Approved Clinical Indications

While currently under review and available in clinical trials in the US and Europe, envafolimab is utilized for the following oncological conditions internationally:

Oncological uses:

• MSI-H/dMMR Solid Tumors: For adult patients with advanced tumors that have specific genetic markers known as “Microsatellite Instability-High” (MSI-H) or “mismatch repair deficiency” (dMMR).
• Advanced Colorectal Cancer: For patients whose cancer has progressed after previous chemotherapy.
• Investigational Sarcomas: Currently being studied in the “ENVASARC” trials for rare soft tissue cancers.

Non-oncological uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Envafolimab is unique because it is administered as an injection under the skin, which typically takes only 30 seconds to a minute.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Current data suggests no specific starting dose adjustments are needed for mild to moderate kidney or liver impairment, but patients are monitored closely for immune-related side effects.
• Toxicity: If a patient develops a severe immune reaction, the doctor may pause the medication or stop it permanently.

Clinical Efficacy and Research Results

Recent clinical studies (2020–2025) have shown that envafolimab is highly effective for tumors with specific genetic “signatures.”

• Tumor Response (MSI-H): In major Phase II trials, the Overall Response Rate (ORR) was approximately 44.2% in patients with MSI-H/dMMR advanced solid tumors. This means nearly half of the patients saw their tumors shrink significantly.
• Survival Rates: For patients who responded to the drug, the response was long-lasting. Data suggests that over 80% of those responders had their cancer stay under control for 12 months or longer.
• Disease Progression: In colorectal cancer trials, envafolimab showed a median Progression-Free Survival (PFS) of roughly 11 months for patients who had failed prior therapies.

Safety Profile and Side Effects

Envafolimab is generally well-tolerated because of its injection method, but like all immunotherapies, it can cause the immune system to attack healthy parts of the body.

Black Box Warning: None.

Common Side Effects (>10%)

• Injection Site Reactions: Redness, swelling, or itching where the needle entered the skin.
• Fatigue: A general feeling of tiredness or lack of energy.
• Rash: Small bumps or itchy patches on the skin.
• Diarrhea: Loose stools or upset stomach.

Serious Adverse Events

• Immune-Related Adverse Events (irAEs): This is when the immune system attacks the lungs (pneumonitis), liver (hepatitis), or colon (colitis).
• Endocrine Issues: Changes in thyroid function or the development of Type 1 Diabetes.

Management Strategies: Most mild side effects are managed with skin creams or rest. Serious immune reactions are treated with steroids (like prednisone) to calm the immune system down.

Research Areas

In the current landscape of 2025–2026, research is heavily focused on Combination Immunotherapy. While there is no direct link to regenerative stem cell therapy yet, scientists are testing envafolimab alongside other “Smart Drugs” and radiation. The goal is to see if envafolimab can “prime” the immune system to remember the cancer, acting almost like a vaccine to prevent the cancer from returning in the future.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

• Genetic Testing: A biopsy is required to confirm if the tumor is MSI-H or dMMR.
• Baseline Blood Work: Testing liver, kidney, and thyroid function.
• Screening for Autoimmune Diseases: To ensure the immune system is safe to be “unlocked.”

Precautions during treatment:

• Monitor for Inflammation: Report any new cough, shortness of breath, or severe stomach pain immediately.
• Site Care: Do not rub or massage the injection site for several hours after treatment.

“Do’s and Don’ts” list:

• DO keep a diary of any new symptoms, even if they seem like common cold symptoms.
• DO stay hydrated and eat a balanced diet.
• DON’T ignore a fever or sudden skin rash.
• DON’T stop or skip doses without talking to your oncologist, as timing is vital for success.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Envafolimab is a prescription medication and should only be used under the supervision of a qualified oncologist. Always seek the advice of your physician regarding your specific diagnosis and treatment options. If you are experiencing a medical emergency, call your local emergency services immediately.